Rising Stronger – Celebrating the Galt Journey and Embracing the Future

Rising Stronger – Celebrating the Galt Journey and Embracing the Future

Barry Patel
Barry Patel

CEO and Co-Founder

As 2024 draws to a close, we take a moment to reflect on an extraordinary year that marks a turning point in our journey. After eight years of perseverance, innovation, and an unwavering commitment to helping patients, 2024 has been our best year yet at Galt Companies.

Galt’s story is one of resilience and determination. As a self-funded company, we’ve faced significant challenges, from navigating the complexities of the pharmaceutical industry to weathering the storm of the Covid-19 pandemic. While the early days tested our resolve, they also defined who we are today—a company built on the foundation of grit, adaptability, and a steadfast mission to serve patients with innovative, non-opioid, non-addictive pain management solutions.

barrrypatel_wadesmith

The pandemic was a particularly difficult chapter, as it limited our ability to connect directly with healthcare providers and disrupted many of our traditional avenues for growth. Rather than retreat, we used those challenges to strengthen our core by finding ways to diversify our approaches to the market. We invested in building robust systems, refining our processes, and aligning our operations to support our unique model—one that prioritizes collaboration with entrepreneurs and local, community-based independent pharmacies. We emerged from those challenging times stronger and more prepared for the opportunities ahead.

And what a year 2024 has been! This year, we added Tolectin®DS to our Norgesic® promotions to give healthcare providers ‘muscle or bone’ options in providing effective pain relief without the risks associated with opioids. We also expanded our distribution network, welcoming new franchisees and independent pharmacy partners who share our vision and values. These collaborations bring our medications to more patients and communities across the country. Additionally, we undertook a comprehensive upgrade of our CRM platforms, empowering our sales professionals and franchisees with cutting-edge tools to better serve healthcare providers and ensure that our products reach those who need them most.

While 2024 has been a banner year, we know it’s just the beginning. The foundation we’ve laid over the past eight years positions us for even greater achievements in the years to come. Our journey continues as we are more motivated than ever to innovate, collaborate, and make a meaningful impact in the lives of patients. To our team, our franchisees, our distributors, our independent pharmacy partners, and all our supporters: thank you for believing in our vision and for being part of this incredible journey. As we look ahead to 2025 and beyond, we do so with excitement and confidence that the best is yet to come.

Here’s to rising stronger together!

 

 

 

The Fentanyl Crisis in the United States

The Fentanyl Crisis in the United States: Understanding the Danger

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

The United States is currently grappling with a severe and escalating public health crisis: the widespread abuse of fentanyl. This synthetic opioid, which is 50 to 100 times more potent than morphine, has become a major driver of overdose deaths across the nation. Understanding why fentanyl is so dangerous is crucial to addressing this urgent issue.

The Rise of Fentanyl

Originally developed for pain management in cancer patients, fentanyl’s medical use was strictly controlled. However, over the past decade, illicit production and distribution have surged. This shift is largely due to fentanyl’s potency and the relative ease with which it can be synthesized in underground laboratories.

Fentanyl is often mixed with other drugs like heroin, cocaine, and methamphetamine, sometimes without the user’s knowledge. This practice increases the risk of overdose significantly, as even a minuscule amount of fentanyl can be lethal. According to the Centers for Disease Control and Prevention (CDC), fentanyl and its analogs were involved in more than 67,000 overdose deaths in the United States in 2021 alone.

Why Fentanyl is So Dangerous

  • Extreme Potency: Fentanyl’s high potency means that very small doses can cause severe respiratory depression and death. This makes it much more dangerous than other opioids. A few milligrams—the equivalent of a few grains of salt—can be lethal.

  • Unpredictable Dosing: When mixed with other drugs, users have no way of knowing the exact dose of fentanyl they are consuming. This unpredictability greatly increases the risk of overdose. Even experienced drug users can easily misjudge the amount, leading to accidental death.

  • Rapid Onset of Effects: Fentanyl acts quickly, often faster than users can react. This rapid onset leaves little time to seek help or administer life-saving interventions such as naloxone, an opioid overdose reversal drug.

  • Availability and Distribution: The illicit production of fentanyl is widespread, and it is often pressed into counterfeit pills that mimic prescription medications. These fake pills can be nearly indistinguishable from legitimate pharmaceuticals, leading to unintentional use by individuals seeking prescription drugs for legitimate purposes.

  • Challenges in Law Enforcement and Healthcare: Detecting and seizing fentanyl is challenging due to its high potency and the small quantities needed for distribution. Additionally, first responders and law enforcement officers are at risk of accidental exposure, which can be fatal. The healthcare system is also strained by the need for increased naloxone availability and the treatment of overdose survivors.

Addressing the Crisis

Efforts to combat the fentanyl crisis require a multifaceted approach. Key strategies include:

  • Education and Prevention: Public awareness campaigns can help inform people about the dangers of fentanyl and the risks of illicit drug use.

  • Enhanced Law Enforcement: Strengthening the capabilities of law enforcement to detect and intercept fentanyl shipments is crucial. This includes international cooperation to dismantle production and distribution networks.

  • Access to Treatment: Expanding access to addiction treatment services and harm reduction programs, such as supervised injection sites and needle exchange programs, can save lives.

  • Improved Data Collection: Better data on overdose deaths and drug use trends can inform targeted interventions and policy decisions.

Conclusion

The fentanyl crisis in the United States is a complex and deadly issue that continues to devastate communities across the nation. Understanding the unique dangers posed by fentanyl is essential for developing effective responses and ultimately saving lives. Through comprehensive efforts encompassing education, enforcement, and treatment, it is possible to mitigate the impact of this crisis and work towards a safer future.

Sources

  1. Centers for Disease Control and Prevention (CDC). “Drug Overdose Deaths in the U.S. Top 100,000 Annually.” Available at: CDC Newsroom
  2. National Institute on Drug Abuse (NIDA). “Fentanyl DrugFacts.” Available at: NIDA
  3. Drug Enforcement Administration (DEA). “Counterfeit Prescription Pills Containing Fentanyls: A Global Threat.” Available at: DEA
  4. By raising awareness and taking decisive action, we can hope to turn the tide on this devastating epidemic.

A Brief History of the Opioid Epidemic

opiods banner

A Brief History of the Opioid Epidemic: What, When, How, and the Effects Today

Scott Chappell
Scott Chappell

Galt Pharmaceuticals Director of Medical Affairs

The opioid epidemic is a complex public health crisis characterized by the widespread misuse and addiction to opioid drugs, including prescription painkillers, heroin, and synthetic opioids, like fentanyl. The epidemic has had devastating consequences, leading to a surge in overdose deaths and profound social and economic impacts.

opiod epidemic

Background and Early Prescription Trends (1990s)

  • What: The opioid epidemic has its roots in the 1990s when there was a significant increase in the prescription of opioid painkillers, driven by reassurances from pharmaceutical companies about the safety and low risk of addiction associated with these medications.
  • When: The surge in opioid prescriptions began in the late 1990s.
  • How: Pharmaceutical companies, including Purdue Pharma, aggressively marketed opioids like OxyContin to healthcare professionals, downplaying the risks of addiction.
  • Citations:
    • Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-227.
    • Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559-574.

       

 Escalation to Heroin (2000s)

  • What: As prescription opioid misuse increased, many individuals turned to heroin as a cheaper and more accessible alternative.
  • When: The transition from prescription opioids to heroin escalated in the mid-2000s.
  • How: Individuals who were addicted to prescription opioids often switched to heroin when their prescriptions ran out or became too expensive.

 Rise of Synthetic Opioids (2010s)

  • What: The opioid crisis worsened with the emergence of powerful synthetic opioids, particularly fentanyl.
  • When: The prevalence of fentanyl increased significantly in the 2010s.
  • How: Fentanyl, often illicitly manufactured, began to be mixed with heroin or sold on its own, contributing to a spike in overdose deaths due to its potency.
  • Citations:
    • Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths – United States, 2010-2015. 
    • MMWR Morb Mortal Wkly Rep. 2016;65(5051):1445-1452.

 Current Effects and Response (2020s)

  • What: The opioid epidemic remains a critical public health challenge, with ongoing efforts to address prevention, treatment, and harm reduction.
  • How: Governments, healthcare providers, and communities are working to expand access to addiction treatment, improve prescribing practices, and enhance education about the risks of opioids.
  • Citations:
    • Substance Abuse and Mental Health Services Administration (SAMHSA). Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health.
    • Centers for Disease Control and Prevention (CDC). Provisional Drug Overdose Death Counts. National Center for Health Statistics.

Impact on Society

The opioid epidemic has had profound social and economic consequences, including strained healthcare systems, increased rates of infectious diseases (e.g., HIV, hepatitis), and a rise in children placed in foster care due to parental substance abuse.

Legal Actions and Litigation

Various lawsuits have been filed against pharmaceutical companies for their role in the opioid epidemic. Purdue Pharma, in particular, faced legal actions, leading to bankruptcy and settlement agreements.

Continued Challenges

Challenges include addressing the stigma associated with addiction, improving access to evidence-based treatment, and finding comprehensive solutions to the social determinants of substance abuse.

While progress has been made in raising awareness and implementing strategies to combat the opioid epidemic, it remains a complex and ongoing public health crisis with multifaceted challenges.